natera™ | Altera™
Tumor genomic profile

Actionable genomic insights for targeted treatment decisions

- **~50–70%** of patients may have a clinically relevant biomarker across major tumor types, yet broad genomic profiling remains underutilized[1]
- **>50%** of oncology trials involve biomarkers, reflecting the growing role of biomarker-defined enrollment and treatment selection[2]

The Altera™ advantage: Precision. Simplicity. Clarity.

1. Deeper insights

Combined DNA whole exome sequencing and RNA whole transcriptome sequencing to enable deeper insights into your patient's tumor genomic alterations for treatment selection and clinical trial opportunities

2. One sample, multiple insights

One sample for both Altera™ + Signatera™ to inform biomarker detection to surveillance

3. Precision diagnostics

Enhanced somatic variant reporting through tumor + normal match sequencing that distinguishes inherited from tumor-specific mutations

Detect what matters with broad whole exome and whole transcriptome sequencing

Altera™ delivers enhanced DNA coverage and comprehensive RNA analysis that identifies both known and novel RNA fusions (e.g. *NTRK*, *RET*) to provide a complete picture of oncogenic drivers.

~14% **more targeted therapy opportunities identified with combined DNA + RNA sequencing vs DNA alone, driven by improved fusion detection[4]**

- **Guideline-recommended biomarkers identified** to support precision oncology decision-making
- **Clinical trial–relevant alterations detected** to help expand treatment opportunities
- **Pertinent negatives reported** to provide clarity and confidence in therapy selection
- **Comprehensive variant detection** (SNVs, indels, CNVs, fusions, splice variants) for a complete molecular profile

Key actionable biomarkers covered by Altera™:

Lung:
BRAF, EGFR, ERBB2 (HER2)*, *KRAS, MET, NRG*

Bladder:
FGFR2/3, HRAS, RB1

CRC:
BRAF, ERBB2 (HER2)*, *KRAS/NRAS, NRG, PIK3CA, POLE/POLD1*

Melanoma:
BRAF, CCND1, CDKN2A, KIT, NRAS

Breast:
AKT1, ERBB2 (HER2)*, *ESR1, BRCA1/2, PALB2, PIK3CA, PTEN*

Pan-tumor:
ALK, MSI/MMR**, *NTRK1/2/3, RET, ROS1,* PD-L1 (22C3), TMB

Order Altera™ today to gain comprehensive genomic insight and support precision treatment decisions

*Altera™ provides both *ERBB2* sequencing and confirmation of HER2 amplification by IHC, offering complementary genomic and protein expression insights.
**MMR deficiency is assessed indirectly through NGS-based MSI analysis.

Note: PD-L1 and HER2 IHC are not included for samples originating from New York.

Informing immunotherapy through comprehensive genomic and MRD insights

Natera oncology integrates biomarker testing, hereditary insights, and recurrence monitoring into a single, seamless platform for faster, more informed treatment decisions.

Clinical case study

55 YEAR-OLD DIAGNOSED WITH STAGE IV CRC



Test ordered:
Altera™ + Empower™ + Signatera™ for comprehensive genomic, germline, and MRD evaluation

Altera™ results: High TMB and MSI-H with *MSH2* potential germline

Empower™ results: Pathogenic *MSH2* mutation detected

- Guide treatment and monitoring with Altera™ results (high TMB/MSI-H) to inform immunotherapy selection, and leverage Signatera™ ctDNA to assess treatment response and detect recurrence earlier than imaging.
- Address hereditary risk of the pathogenic *MSH2* finding from Empower™ by referring patients for genetic counseling and initiating cascade testing for at-risk relatives.

We deliver a seamless experience that provides the molecular insights you depend on throughout the patient journey. From therapy selection to surveillance monitoring, our best-in-class platform streamlines the testing pathway.

Note: Real-world Signatera™ case from study. Case features modified for illustrative purposes to protect patient confidentiality. No treatment recommendations are made or should be implied.

Oncology platform designed for real-world oncology practices

Single tissue sample for Altera™ + Signatera™, reducing specimen burden

Reports include built-in therapy guidance by level of evidence, clinical trial matching, and curated reporting

Altera™ includes assessment of key immune biomarkers (TMB and MSI) and immunohistochemistry (IHC) evaluation of HER2 and PD-L1 to support therapeutic decision-making

Integrated hereditary cancer testing from a single order form

Comprehensive, accessible financial support

Natera also offers various programs to provide access to affordable testing for eligible patients, including self-pay options, interest-free payment plans, and Natera's Financial Assistance Program to access testing at a reduced rate for eligible patients.

Financial assistance form: care.natera.com

Precision oncology doesn't have to be complicated.
To learn more about Altera™, visit **www.natera.com/oncology/altera**

References: 1. Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. *Nat Med.* 2019;25(5):744-750. doi:10.1038/s41591-019-0407-5 **2.** Hanna GJ, Rafei H, Chau NG, et al. Clinical utility of comprehensive genomic profiling in advanced cancer: contemporary applications and considerations. *J Appl Lab Med*. 2023;9(1):76-89. **3.** Personalized Medicine Coalition. The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments. Personalized Medicine Coalition; 2019. Accessed February 19, 2026. **4.** Benayed R, Offin M, Mullaney K, et al. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alterations Detected by DNA Sequencing and Low Tumor Mutation Burden. *Clin Cancer Res.* 2019;25(15):4712–4722. doi:10.1158/1078-0432.CCR-19-0225t

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved. ALT_BR_Altera_BiFold_20260527_NAT-8023812

natera™